

# Criteria-Based Consultation Prescribing Program

## CRITERIA FOR DRUG COVERAGE

### Sacubitril-Valsartan (Entresto)

#### Notes:

- Quantity Limits: Yes

**Initiation (new start) criteria:** Non-formulary **sacubitril-valsartan (Entresto)** will be covered on the prescription drug benefit when the following criteria are met:

- Prescribed by or in consultation with a cardiologist – AND-
- Documented heart failure diagnosis on the Problem List – AND-
- Patient has left ventricular ejection fraction (LVEF; measurement of the percent of blood leaving your heart each time it contracts) 40% or less – AND-
- No history of angioedema (swelling underneath the skin) related to previous angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker therapy

**Criteria for current Kaiser Permanente members already taking the medication who have not been reviewed previously:** Non-formulary **sacubitril-valsartan (Entresto)** will be covered on the prescription drug benefit when the following criteria are met:

- Prescribed by or in consultation with a cardiologist – AND-
- Documented heart failure diagnosis on the Problem List – AND-
- Patient has left ventricular ejection fraction (LVEF; measurement of the percent of blood leaving your heart each time it contracts) 40% or less – AND-
- No history of angioedema (swelling underneath the skin) related to previous angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker therapy

**Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously:** Non-formulary **sacubitril-valsartan (Entresto)** will be covered on the prescription drug benefit when the following criteria are met:

- Prescribed by or in consultation with a cardiologist – AND-
- Documented heart failure diagnosis on the Problem List – AND-
- Patient has left ventricular ejection fraction (LVEF; measurement of the percent of blood leaving your heart each time it contracts) 40% or less – AND-
- No history of angioedema (swelling underneath the skin) related to previous angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker therapy